Treatment of antiviral therapy for chronic hepatitis B: A disease in evolution
- Cite this article as:
- Satheesh, S. & Perrillo, R.P. Curr hepatitis rep (2005) 4: 14. doi:10.1007/s11901-005-0021-5
There have been many exciting developments in the treatment of chronic hepatitis B during the past several years. Interferon, adefovir, and lamivudine are currently licensed therapies, and several promising nucleoside analogues that are capable of treating both wild-type and lamivudine-resistant forms of hepatitis B virus are in latestage development. Pegylated interferon has been shown to have greater antiviral activity when compared with conventional interferon. Each of these drugs has advantages and disadvantages. The greatest challenge for the future will reside in how to best use these agents, either alone or in combination, so as to maximize therapeutic benefit.